Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4142
Title: | Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles? | Authors: | Moore, Andrew Kunarajah, K. Hennig, S. Norris, R. L. G. Lobb, M. Charles, B. G. Pinkerton, R. |
Issue Date: | 2017 | Source: | 80, (1), 2017, p. 15-25 | Pages: | 15-25 | Journal: | Cancer Chemotherapy and Pharmacology | Abstract: | Purpose: Anthracyclines are a mainstay of the treatment of several childhood malignancies, but their utility is limited by dose-related cardiotoxicity. This study is aimed to explore the link between exposure of paediatric cancer patients to doxorubicin and its metabolite doxorubicinol, and cardiac troponin I (cTnI). Methods: In a prospective pilot study plasma doxorubicin, doxorubicinol, and cTnI concentrations were measured in samples from children undergoing cancer chemotherapy. A mixed-effects population pharmacokinetic model for doxorubicin and doxorubicinol and in combination with a turn-over model for cTnI were developed. Results: Seventeen patients, aged 3.4–14.7 year, treated for a variety of cancers had 99 doxorubicin and 119 doxorubicinol concentrations analysed from samples drawn between 0.5 and 336 h after the start of the infusion. Eleven patients had received previous doses of anthracyclines, with a median cumulative prior dose of 90 mg/m2 (range 0–225 mg/m2). The median administered doxorubicin dose was 30 mg/m2 (range 25–75 mg/m2). Doxorubicin disposition was described by a three-compartment model with first-order elimination and metabolism to doxorubicinol. Body surface area was related to all clearance and distribution parameters and age further influenced clearance (CL, 58.7 L/h/1.8 m2 for an average 8.4-year-old patient). Combined doxorubicin and metabolite exposure stimulated a temporary increase in cTnI in plasma, with a concentration of 11.8 µg/L required to achieve half-maximal effect. Prior cumulative anthracycline dosage received by patients was predictive of an increased cTnI baseline prior to a new doxorubicin dose. Conclusion: Prior anthracycline exposure increased baseline cTnI in a dose-dependent manner, consistent with the known cumulative risk of anthracycline exposure-induced cardiotoxicity.L6157025802017-05-02 | DOI: | 10.1007/s00280-017-3309-6 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L615702580&from=exporthttp://dx.doi.org/10.1007/s00280-017-3309-6 | | Keywords: | drug distribution;drug effect;drug elimination;drug exposure;drug metabolism;female;hepatoblastoma;Hodgkin disease;human;male;multiple cycle treatment;nephroblastoma;neuroblastoma;nonhodgkin lymphoma;osteosarcoma;pilot study;population;preschool child;priority journal;prospective study;school child;synovial sarcoma;turnover rate;anthracyclinedoxorubicin;doxorubicinol;troponin I;acute lymphoblastic leukemia;adolescent;article;body surface;cancer combination chemotherapy;cancer patient;cardiotoxicity;child;childhood cancer;clinical article;concentration response;disease association;distribution parameters;drug blood level;drug clearance;drug disposition | Type: | Article |
Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.